A Single Tuesday in Neuro: LB-102, ATH434, and AbbVie’s $1.4B Bet
Two Phase 2 readouts and a billion-dollar factory landed the same day. Worth reading together.
Jeff Martin
Read MoreA Single Tuesday in Neuro: LB-102, ATH434, and AbbVie’s $1.4B Bet
No news or media at this time
A $354M financing into a CNS program isn’t just a headline—it’s a signal. After years of hesitation, serious capital is re-engaging in neurology with a sharper lens on mechanism, patient selection, and clinical path.